BRPI0718041A2 - Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos - Google Patents

Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos

Info

Publication number: BRPI0718041A2
Authority: BR; Brazil
Prior art keywords: angiotensin; cats; prevention; treatment; receptor antagonist
Prior art date: 2006-10-06

Application number

Other languages

English (en)

Inventor

Marcus Stark

Ulrike Sent

Ingo Lang

Original Assignee

Boehringer Ingelheim Vetmed

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-06

Filing date

2007-10-04

Publication date

2015-05-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37744125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0718041(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-10-04 Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed

2007-10-04 Priority to BRBR122013019533-5A priority Critical patent/BR122013019533A2/pt

2007-10-04 Priority to BRBR122013019534-3A priority patent/BR122013019534A2/pt

2007-10-04 Priority to BRBR122013019535-1A priority patent/BR122013019535A2/pt

2015-05-12 Publication of BRPI0718041A2 publication Critical patent/BRPI0718041A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0718041 2006-10-06 2007-10-04 Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos BRPI0718041A2 (pt)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
BRBR122013019533-5A BR122013019533A2 (pt)	2006-10-06	2007-10-04	Uso de um antagonista do receptor da angiotensina ii para produção de uma composição farmacêutica para prevenção ou tratamento de hipertensão sistêmica em gatos
BRBR122013019534-3A BR122013019534A2 (pt)	2006-10-06	2007-10-04	Uso de um antagonista do receptor da angiotensina ii para produção de uma composição farmacêutica para prevenção ou tratamento de doenças cardiovasculares em gatos
BRBR122013019535-1A BR122013019535A2 (pt)	2006-10-06	2007-10-04	Uso de um antagonista do receptor da angiotensina ii para produção de uma composição farmacêutica para prevenção ou tratamento de doenças vasculares ou distúrbios metabólicos e/ou doença sistêmica em gatos

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06121905A EP1908469A1 (en)	2006-10-06	2006-10-06	Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
PCT/EP2007/060531 WO2008040774A2 (en)	2006-10-06	2007-10-04	Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats

Publications (1)

Publication Number	Publication Date
BRPI0718041A2 true BRPI0718041A2 (pt)	2015-05-12

Family

ID=37744125

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
BRBR122013019534-3A BR122013019534A2 (pt)	2006-10-06	2007-10-04	Uso de um antagonista do receptor da angiotensina ii para produção de uma composição farmacêutica para prevenção ou tratamento de doenças cardiovasculares em gatos
BRBR122013019535-1A BR122013019535A2 (pt)	2006-10-06	2007-10-04	Uso de um antagonista do receptor da angiotensina ii para produção de uma composição farmacêutica para prevenção ou tratamento de doenças vasculares ou distúrbios metabólicos e/ou doença sistêmica em gatos
BRPI0718041 BRPI0718041A2 (pt)	2006-10-06	2007-10-04	Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos
BRBR122013019533-5A BR122013019533A2 (pt)	2006-10-06	2007-10-04	Uso de um antagonista do receptor da angiotensina ii para produção de uma composição farmacêutica para prevenção ou tratamento de hipertensão sistêmica em gatos

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
BRBR122013019534-3A BR122013019534A2 (pt)	2006-10-06	2007-10-04	Uso de um antagonista do receptor da angiotensina ii para produção de uma composição farmacêutica para prevenção ou tratamento de doenças cardiovasculares em gatos
BRBR122013019535-1A BR122013019535A2 (pt)	2006-10-06	2007-10-04	Uso de um antagonista do receptor da angiotensina ii para produção de uma composição farmacêutica para prevenção ou tratamento de doenças vasculares ou distúrbios metabólicos e/ou doença sistêmica em gatos

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BRBR122013019533-5A BR122013019533A2 (pt)	2006-10-06	2007-10-04	Uso de um antagonista do receptor da angiotensina ii para produção de uma composição farmacêutica para prevenção ou tratamento de hipertensão sistêmica em gatos

Country Status (25)

Country	Link
US (5)	US8772278B2 (pt)
EP (5)	EP1908469A1 (pt)
JP (5)	JP5425631B2 (pt)
KR (2)	KR101529541B1 (pt)
CN (6)	CN105148272A (pt)
AR (1)	AR063155A1 (pt)
BR (4)	BR122013019534A2 (pt)
CA (1)	CA2665435C (pt)
CL (2)	CL2007002897A1 (pt)
CO (1)	CO6180425A2 (pt)
CY (2)	CY1114266T1 (pt)
DK (4)	DK2420231T3 (pt)
ES (4)	ES2425482T3 (pt)
HR (1)	HRP20130696T1 (pt)
HU (4)	HUE027399T2 (pt)
LU (1)	LU92282I2 (pt)
MX (4)	MX2009002340A (pt)
NL (1)	NL300616I2 (pt)
NZ (3)	NZ576109A (pt)
PL (4)	PL2420232T3 (pt)
PT (1)	PT2086535E (pt)
SI (1)	SI2086535T1 (pt)
TW (3)	TWI415605B (pt)
WO (1)	WO2008040774A2 (pt)
ZA (1)	ZA200901218B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1908469A1 (en) *	2006-10-06	2008-04-09	Boehringer Ingelheim Vetmedica Gmbh	Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
AR068814A1 (es) *	2007-08-29	2009-12-09	Orion Corp	Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
WO2010097501A2 (en) *	2009-02-26	2010-09-02	Orion Corporation	A combination treatment
EP2432452B1 (de)	2009-05-20	2016-07-27	Boehringer Ingelheim Vetmedica GmbH	Pharmazeutische telmisartan-trinklösung
CN102283832B (zh) *	2011-09-09	2013-04-10	南京正宽医药科技有限公司	一种预防或治疗高血压肥胖患者的药物组合物及用途
EP3682902A1 (en)	2012-05-18	2020-07-22	Luoda Pharma Limited	Liquid formulation
DE102012018903A1 (de)	2012-09-26	2014-03-27	Elisabeth Kurth	Brustglocke für die manuelle Laktation von Milch aus der weiblichen Brust
CN105233288A (zh) *	2015-09-28	2016-01-13	青岛云天生物技术有限公司	一种治疗或预防肥胖型高血压的药物组合物及其用途
JP6800633B2 (ja) *	2016-07-04	2020-12-16	株式会社カネカ	非ヒト動物において腎機能の低下を抑制する方法
PT3648761T (pt) *	2017-07-07	2024-06-05	Boehringer Ingelheim Vetmedica Gmbh	Telmisartan para a profilaxia ou tratamento de hipertensão em gatos
KR20220054292A (ko) *	2019-07-09	2022-05-02	베링거잉겔하임베트메디카게엠베하	개의 고혈압 치료를 위한 텔미사르탄
US20240058309A1 (en) *	2020-12-28	2024-02-22	Cured Inc.	Pharmaceutical composition for treating chronic kidney disease
KR20260019532A (ko)	2023-05-24	2026-02-10	베링거잉겔하임베트메디카게엠베하	하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1023027B (de)	1953-07-10	1958-01-23	Hoffmann La Roche	Verfahren zur Herstellung von Polyendialdehyden
JPS5671074A (en)	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4448778A (en)	1981-08-03	1984-05-15	Ici Americas Inc.	Maltitol containing gel base systems
CA1334092C (en)	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
US5015651A (en)	1988-01-07	1991-05-14	E. I. Du Pont De Nemours And Company	Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en)	1988-01-07	1996-04-09	David John Carini	Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en)	1988-01-07	1989-11-14	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking benzimidazoles
IE70593B1 (en)	1989-09-29	1996-12-11	Eisai Co Ltd	Biphenylmethane derivative the use of it and pharmacological compositions containing same
DE122007000050I1 (de)	1990-02-19	2007-11-08	Novartis Ag	Acylverbindungen
TW201738B (pt)	1990-03-20	1993-03-11	Sanofi Co
US5196444A (en)	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en)	1990-09-10	1992-07-15	Abbott Lab	Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
US6028091A (en)	1990-12-14	2000-02-22	Smithkline Beecham Plc	Medicament
GB9027210D0 (en)	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
US5591762A (en)	1991-02-06	1997-01-07	Dr. Karl Thomae Gmbh	Benzimidazoles useful as angiotensin-11 antagonists
SI9210098B (sl)	1991-02-06	2000-06-30	Dr. Karl Thomae	Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en)	1991-03-21	1993-03-23	G. D. Searle & Co.	5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en)	1991-05-16	1991-07-03	Glaxo Group Ltd	Chemical compounds
AU675935B2 (en)	1992-04-13	1997-02-27	Astrazeneca Ab	Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy
JP3862295B2 (ja) *	1993-09-30	2006-12-27	独立行政法人理化学研究所	抗肥満剤
CA2186606A1 (en)	1994-03-29	1995-10-05	Edward B. Nelson	Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
CZ313897A3 (cs) *	1995-04-07	1998-01-14	Novartis Ag	Farmaceutické kompozice obsahující benazepril nebo benazeprilát a valsartan
JP2000513356A (ja) *	1996-06-24	2000-10-10	メルクエンドカンパニーインコーポレーテッド	エナラプリルとロサルタンの組成物
JPH11315034A (ja) *	1998-03-04	1999-11-16	Takeda Chem Ind Ltd	アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
AU2745199A (en)	1998-03-04	1999-09-20	Takeda Chemical Industries Ltd.	Sustained-release preparation for aii antagonist, production and use thereof
US6204281B1 (en) *	1998-07-10	2001-03-20	Novartis Ag	Method of treatment and pharmaceutical composition
DE19901921C2 (de)	1999-01-19	2001-01-04	Boehringer Ingelheim Pharma	Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
US6358986B1 (en)	1999-01-19	2002-03-19	Boehringer Ingelheim Pharma Kg	Polymorphs of telmisartan
DE10018401A1 (de) *	2000-04-13	2001-10-25	Boehringer Ingelheim Pharma	Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
WO2002030400A1 (fr) *	2000-10-06	2002-04-18	Takeda Chemical Industries, Ltd.	Preparations solides
US20030073705A1 (en)	2001-05-14	2003-04-17	Shahnaz Shahinfar	Method of treatment
US20040219208A1 (en) *	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
US6737432B2 (en)	2001-10-31	2004-05-18	Boehringer Ingelheim Pharma Kg	Crystalline form of telmisartan sodium
DE10153737A1 (de)	2001-10-31	2003-05-28	Boehringer Ingelheim Pharma	Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
JP2005531558A (ja) *	2002-05-17	2005-10-20	ノバルティスアクチエンゲゼルシャフト	心筋梗塞の二次予防のためのアンギオテンシンＩＩ受容体ブロッカーおよびβブロッカーの組合せ
US7232828B2 (en) *	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US20050272649A1 (en) *	2002-08-28	2005-12-08	Hruska Keith A	Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
DE10244681A1 (de)	2002-09-24	2004-04-08	Boehringer Ingelheim International Gmbh	Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
US8980870B2 (en) *	2002-09-24	2015-03-17	Boehringer Ingelheim International Gmbh	Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) *	2003-07-31	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Angiotensin II Rezeptor Antagonisten
US20050187262A1 (en) *	2004-01-12	2005-08-25	Grogan Donna R.	Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
DE102004008804A1 (de) *	2004-02-20	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Mehrschichttablette
EP1579862A1 (en) *	2004-03-25	2005-09-28	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
WO2005123070A1 (en) *	2004-06-09	2005-12-29	Fibrogen, Inc.	Dual blockade of renin-angiotensin system reduces connective tissue growth factor levels in diabetic nephropathy
CN1602960A (zh) *	2004-07-23	2005-04-06	海南国栋药物研究所有限公司	一种防治心脑血管病及糖尿病等代谢综合症的复合制剂
CN100364532C (zh) *	2004-09-30	2008-01-30	江苏恒瑞医药股份有限公司	包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
ME01615B (me) *	2004-11-05	2014-09-20	Boehringer Ingelheim Int	Dvoslojna tableta koja sadrži telmisartan i amlodipin
CN1813707A (zh) *	2004-12-01	2006-08-09	鲁南制药集团股份有限公司	用于治疗高血压的含有单硝酸异山梨酯的药物组合物
US20070026026A1 (en) *	2005-08-01	2007-02-01	David Delmarre	Oral liquid losartan compositions
EP1908469A1 (en)	2006-10-06	2008-04-09	Boehringer Ingelheim Vetmedica Gmbh	Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP1970053A1 (en)	2007-03-14	2008-09-17	Boehringer Ingelheim Pharma GmbH & Co. KG	Pharmaceutical composition
EP2432452B1 (de)	2009-05-20	2016-07-27	Boehringer Ingelheim Vetmedica GmbH	Pharmazeutische telmisartan-trinklösung

2006
- 2006-10-06 EP EP06121905A patent/EP1908469A1/en not_active Ceased
2007
- 2007-10-04 PL PL11186078T patent/PL2420232T3/pl unknown
- 2007-10-04 MX MX2009002340A patent/MX2009002340A/es active IP Right Grant
- 2007-10-04 ES ES07820908T patent/ES2425482T3/es active Active
- 2007-10-04 HR HRP20130696TT patent/HRP20130696T1/hr unknown
- 2007-10-04 JP JP2009530883A patent/JP5425631B2/ja active Active
- 2007-10-04 MX MX2013004347A patent/MX360148B/es unknown
- 2007-10-04 ES ES11186070.6T patent/ES2565519T3/es active Active
- 2007-10-04 CN CN201510336736.0A patent/CN105148272A/zh active Pending
- 2007-10-04 PL PL11186080T patent/PL2420233T3/pl unknown
- 2007-10-04 DK DK11186070.6T patent/DK2420231T3/en active
- 2007-10-04 CA CA2665435A patent/CA2665435C/en active Active
- 2007-10-04 KR KR1020147014825A patent/KR101529541B1/ko active Active
- 2007-10-04 CN CN2011104188656A patent/CN102512678A/zh active Pending
- 2007-10-04 PL PL11186070T patent/PL2420231T3/pl unknown
- 2007-10-04 BR BRBR122013019534-3A patent/BR122013019534A2/pt not_active Application Discontinuation
- 2007-10-04 DK DK07820908.7T patent/DK2086535T3/da active
- 2007-10-04 MX MX2013004348A patent/MX360147B/es unknown
- 2007-10-04 DK DK11186078.9T patent/DK2420232T3/en active
- 2007-10-04 MX MX2013004349A patent/MX360150B/es unknown
- 2007-10-04 NZ NZ576109A patent/NZ576109A/en unknown
- 2007-10-04 PL PL07820908T patent/PL2086535T3/pl unknown
- 2007-10-04 ES ES11186078.9T patent/ES2562182T3/es active Active
- 2007-10-04 EP EP11186080.5A patent/EP2420233B1/en active Active
- 2007-10-04 CN CN201210056647.7A patent/CN102580095B/zh active Active
- 2007-10-04 WO PCT/EP2007/060531 patent/WO2008040774A2/en not_active Ceased
- 2007-10-04 PT PT78209087T patent/PT2086535E/pt unknown
- 2007-10-04 BR BRBR122013019535-1A patent/BR122013019535A2/pt not_active Application Discontinuation
- 2007-10-04 CN CN201811093737.7A patent/CN109125730A/zh active Pending
- 2007-10-04 HU HUE11186070A patent/HUE027399T2/en unknown
- 2007-10-04 EP EP11186078.9A patent/EP2420232B1/en active Active
- 2007-10-04 DK DK11186080.5T patent/DK2420233T3/en active
- 2007-10-04 CN CN202111463480.1A patent/CN114344293B/zh active Active
- 2007-10-04 BR BRPI0718041 patent/BRPI0718041A2/pt not_active Application Discontinuation
- 2007-10-04 CN CN2007800374949A patent/CN101522191B/zh active Active
- 2007-10-04 SI SI200731289T patent/SI2086535T1/sl unknown
- 2007-10-04 NZ NZ609533A patent/NZ609533A/en unknown
- 2007-10-04 KR KR1020097009113A patent/KR101456151B1/ko active Active
- 2007-10-04 ES ES11186080.5T patent/ES2567041T3/es active Active
- 2007-10-04 EP EP11186070.6A patent/EP2420231B1/en active Active
- 2007-10-04 NZ NZ597648A patent/NZ597648A/xx unknown
- 2007-10-04 HU HUE11186078A patent/HUE027280T2/en unknown
- 2007-10-04 EP EP07820908.7A patent/EP2086535B1/en active Active
- 2007-10-04 BR BRBR122013019533-5A patent/BR122013019533A2/pt not_active Application Discontinuation
- 2007-10-05 TW TW096137618A patent/TWI415605B/zh active
- 2007-10-05 CL CL200702897A patent/CL2007002897A1/es unknown
- 2007-10-05 TW TW102114897A patent/TWI539949B/zh active
- 2007-10-05 US US11/973,250 patent/US8772278B2/en active Active
- 2007-10-05 TW TW102133689A patent/TWI539950B/zh active
- 2007-10-09 AR ARP070104427A patent/AR063155A1/es unknown
2009
- 2009-02-20 ZA ZA200901218A patent/ZA200901218B/xx unknown
- 2009-04-06 CO CO09035442A patent/CO6180425A2/es not_active Application Discontinuation
2012
- 2012-05-24 CL CL2012001349A patent/CL2012001349A1/es unknown
2013
- 2013-03-13 US US13/799,768 patent/US9308197B2/en active Active
- 2013-08-01 JP JP2013160676A patent/JP5899165B2/ja active Active
- 2013-08-01 JP JP2013160675A patent/JP6151123B2/ja active Active
- 2013-08-21 CY CY20131100712T patent/CY1114266T1/el unknown
- 2013-09-18 NL NL300616C patent/NL300616I2/nl unknown
- 2013-09-18 CY CY2013037C patent/CY2013037I2/el unknown
- 2013-09-19 LU LU92282C patent/LU92282I2/fr unknown
- 2013-10-21 HU HUS1300062C patent/HUS1300062I1/hu unknown
2014
- 2014-06-02 US US14/293,472 patent/US9585873B2/en active Active
2015
- 2015-12-07 JP JP2015238531A patent/JP2016094436A/ja active Pending
2017
- 2017-01-20 US US15/411,062 patent/US9949954B2/en active Active
- 2017-03-06 JP JP2017042000A patent/JP6337170B2/ja active Active
2018
- 2018-03-08 US US15/915,817 patent/US10357479B2/en active Active
- 2018-11-08 HU HUS1800044C patent/HUS1800044I1/hu unknown

Also Published As

Publication number	Publication date
US20140288138A1 (en)	2014-09-25
TW201332547A (zh)	2013-08-16
HUE027399T2 (en)	2016-09-28
AR063155A1 (es)	2008-12-30
TWI539950B (zh)	2016-07-01
NZ597648A (en)	2013-05-31
HRP20130696T1 (hr)	2013-09-30
JP6151123B2 (ja)	2017-06-21
TW200831078A (en)	2008-08-01
HUS1300062I1 (hu)	2013-11-28
JP2016094436A (ja)	2016-05-26
US9308197B2 (en)	2016-04-12
DK2420231T3 (en)	2016-04-11
CN105148272A (zh)	2015-12-16
KR20090080954A (ko)	2009-07-27
CN114344293A (zh)	2022-04-15
LU92282I9 (pt)	2019-01-17
US9585873B2 (en)	2017-03-07
DK2420232T3 (en)	2016-03-07
EP2420231B1 (en)	2016-01-13
NZ576109A (en)	2012-02-24
TW201402115A (zh)	2014-01-16
MX2009002340A (es)	2009-03-23
CN102512678A (zh)	2012-06-27
WO2008040774A2 (en)	2008-04-10
US20180193317A1 (en)	2018-07-12
PL2420233T3 (pl)	2016-07-29
ZA200901218B (en)	2010-03-31
AU2007304216A1 (en)	2008-04-10
CN101522191A (zh)	2009-09-02
MX360148B (es)	2018-10-24
US20130190373A1 (en)	2013-07-25
ES2562182T3 (es)	2016-03-02
HUE027280T2 (en)	2016-09-28
EP2420233B1 (en)	2016-01-13
JP2013216708A (ja)	2013-10-24
CN102580095B (zh)	2015-12-09
US20170128423A1 (en)	2017-05-11
CL2012001349A1 (es)	2012-10-12
EP2086535A2 (en)	2009-08-12
JP5899165B2 (ja)	2016-04-06
US20080146543A1 (en)	2008-06-19
EP2420231A3 (en)	2012-04-11
DK2420233T3 (en)	2016-04-11
EP2420232A3 (en)	2012-05-02
JP5425631B2 (ja)	2014-02-26
AU2007304216B2 (en)	2013-06-13
PL2420231T3 (pl)	2016-07-29
CN101522191B (zh)	2012-05-16
ES2425482T3 (es)	2013-10-15
TWI539949B (zh)	2016-07-01
JP2017122115A (ja)	2017-07-13
MX360150B (es)	2018-10-24
KR101456151B1 (ko)	2014-11-04
EP1908469A1 (en)	2008-04-09
US9949954B2 (en)	2018-04-24
CA2665435A1 (en)	2008-04-10
PL2086535T3 (pl)	2013-10-31
HUS1800044I1 (hu)	2018-12-28
BR122013019533A2 (pt)	2015-07-14
PT2086535E (pt)	2013-08-22
JP2010505796A (ja)	2010-02-25
ES2565519T3 (es)	2016-04-05
KR20140088601A (ko)	2014-07-10
KR101529541B1 (ko)	2015-06-17
ES2567041T3 (es)	2016-04-19
CN109125730A (zh)	2019-01-04
DK2086535T3 (da)	2013-07-22
MX360147B (es)	2018-10-24
JP2013216709A (ja)	2013-10-24
CO6180425A2 (es)	2010-07-19
CN114344293B (zh)	2024-04-19
EP2420233A3 (en)	2012-04-18
CY1114266T1 (el)	2015-11-04
EP2420232A2 (en)	2012-02-22
EP2420231A2 (en)	2012-02-22
TWI415605B (zh)	2013-11-21
BR122013019534A2 (pt)	2015-07-14
CA2665435C (en)	2016-03-29
EP2086535B1 (en)	2013-05-22
CY2013037I1 (el)	2015-11-04
NL300616I2 (pt)	2016-06-01
EP2420233A2 (en)	2012-02-22
US8772278B2 (en)	2014-07-08
EP2420232B1 (en)	2016-01-06
CY2013037I2 (el)	2015-11-04
PL2420232T3 (pl)	2016-06-30
US10357479B2 (en)	2019-07-23
WO2008040774A3 (en)	2008-07-10
BR122013019535A2 (pt)	2015-07-14
NZ609533A (en)	2014-08-29
LU92282I2 (fr)	2013-11-19
SI2086535T1 (sl)	2013-09-30
CL2007002897A1 (es)	2008-03-07
CN102580095A (zh)	2012-07-18
JP6337170B2 (ja)	2018-06-06

Publication	Publication Date	Title
BRPI0718041A2 (pt)	2015-05-12	Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BRPI0720178A2 (pt)	2013-12-24	Derivados de 2,3-di-hidroimidazo[1,2-c]quinazolina substituída úteis para tratar distúrbios e doenças hiperproliferativos associados com angiogênese
PL2468290T3 (pl)	2015-08-31	Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
BRPI1009860A2 (pt)	2016-03-08	composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais
IL196470A (en)	2016-07-31	Antagonist antibody for the treatment of cancer
BRPI0716844A2 (pt)	2013-10-22	Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0815588A2 (pt)	2015-02-18	Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
DK2399580T3 (da)	2013-06-24	Farmaceutiske doseringsformer
BRPI0716893A2 (pt)	2014-05-06	Forma de dosagem sólida de olmesartan medoxomila e anlodipina
IL199045A0 (en)	2010-03-28	Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP2146620A4 (en)	2011-07-06	ANOSKOP FOR INSPECTION AND / OR OPERATION
EP2154966A4 (en)	2010-12-15	BENZIMIDAZOLE AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
IL195427A0 (en)	2009-08-03	Muscarinic receptor agonists that are effective in the treatment of pain, alzheimers disease and schizophrenia
EP1984004A4 (en)	2010-03-03	THE THERAPY REINFORCING GLUCAN
BRPI0814177A2 (pt)	2015-01-20	Derivados de 1-oxo-1,2-di-hidroisoquinoleína-5-carboxamidas e de 4-oxo-3,4-di-hidroquinazolina-8-carboxamidas, sua preparação e sua aplicação em terapêutica
HUE065668T2 (hu)	2024-06-28	Delmopinollal bevont, állatoknak való rágóka halitózis megelõzésében vagy kezelésében történõ alkalmazásra
FI20095661L (fi)	2009-06-12	Toimijan henkilöllisyyden varmennus
BRPI0714318A2 (pt)	2014-06-24	Utilização de 2-benzoil-imidazopiridinas em terapêutica
EP2029116A4 (en)	2012-07-04	SEGMENTED PHARMACEUTICAL DOSAGE FORMS
EP2100588A4 (en)	2011-01-19	PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST ALOPEY
EP1776956A4 (en)	2010-05-12	MEANS FOR THE PREVENTION AND / OR TREATMENT OF CALCIPENIA
EP2057997A4 (en)	2012-11-07	MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERIPHERAL NEUROPATHY
BRPI0908602A2 (pt)	2019-09-24	método e composição farmacêutica para o tratamento de doenças autoimunes.
ZA200904382B (en)	2010-08-25	Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-retaled diseases

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-04-24	B07G	Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]	Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.
2019-06-25	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-10-15	B09B	Patent application refused [chapter 9.2 patent gazette]
2019-12-17	B12B	Appeal against refusal [chapter 12.2 patent gazette]